TABLE 6.
Meropenem dosing recommendation against pathogens with MIC values of ≤2 mg/L
| CLCR-CG (mL/min)a |
fT>MIC targeta |
||
|---|---|---|---|
| 40% fT>MIC | 75% fT>MIC | 100% fT>MIC | |
| 90.1 to 130 | LD 2 g, 1 g q8h (II)b | LD 2 g, 1 g q6h (EI) | LD 2 g, 2 g q6h (EI) |
| 50.1 to 90 | LD 2 g, 1 g q8h (II)b | LD 2 g, 1 g q8h (EI) | LD 2 g, 2 g q6h (EI) |
| 25.1 to 50 | LD 2 g, 1 g q12h (II)b | LD 2 g, 1 g q12h (EI) | LD 2 g, 1 g q6h (EI) |
| 10 to 25 | LD 1 g, 0.5 g q12h (II)b | LD 1 g, 0.5 g q12h (II)b | LD 1g, 0.5 g q6h (II) |
| <10 | LD 1 g, 0.5 g q24h (II)b | LD 1 g, 0.5 g q24h (II)b | LD 1 g, 0.5 g q8h (II) |
a
%fT>MIC, percentage of dosing interval where unbound meropenem concentration is above the MIC; CLCR-CG, creatinine clearance estimated using standard Cockcroft-Gault formula based on ideal body weight; LD, loading dose; II, intermittent infusion (0.5 h); EI, extended infusion (3 h).
b
Current standard regimen according to drug label information.